Momotaro-Gene Inc. is a biotechnology venture company spun out of Okayama University. The company mission is to bridge technological seeds from academia to the industry or collaboration with the industry to launch new drug to the market. Momotaro-Gene's first technology is REIC/Dkk-3 gene therapy. This gene was isolated and cloned at Okayama University by Prof. Namba and his team in the early 2000’s. Later, Prof. Kumon, former Chair of Urology Dept., led the initiation of clinical development and established the company in 2007.


Kyorin Pharmaceutical licensed the REIC technology for malignant mesothelioma in September, 2015 for the territory of Japan only. Kyorin has worked with Momotaro-Gene Inc. and MTG Biotherapeutics to move into the first clinical trial for mesothelioma using MTG-201 in Japan.


EPS Co. Ltdhas acquired rights for the REIC technology for use in China from Momotaro-Gene Inc.